PSMO-09 - 83 - Neurodegenerative diseases: From innovation to patient impact

Last updated: May 1, 2026, 5:06 am

« Back to Agenda

PSMO-09 - 83 - Neurodegenerative diseases: From innovation to patient impact

Tracks
Track 5
Monday, August 31, 2026
2:30 PM - 4:00 PM

Details

Organised by the FIP New Generation of Scientists Special Interest Group in collaboration with the FIP Early Career Pharmaceutical Group, the FIP Hospital Pharmacy Section and the FIP Industrial Pharmacy Section Chair(s) Ms Nikolina Biskic, Executive Committee Associate Member, the FIP Industrial Pharmacy Section, Croatia & Prof. Michael Ward, Co-chair, FIP Congress Programme Development Group, Australia Introduction: This session explores how innovation in neurodegenerative disease research translates into clinical practice and improves patients’ quality of life. It aims to connect scientists developing novel therapeutic approaches -such as metabolic, gene, or cell-based interventions with pharmacists providing care and supporting patients and families in daily disease management. The session will also emphasise the importance of interdisciplinary collaboration and communication between researchers, practitioners, and caregivers. In line with the congress theme, the session will highlight how scientific innovation translates into integrated care pathways and tangible patient outcomes, with pharmacists playing a key role across research, clinical implementation, and long-term patient support. Programme:
14:30 – 14:40 Introduction by the chairs
14:40 – 15:00 Advanced treatments for neuromuscular disorders: Real world experiences in a global population
Ms Christina Hellauer, Children’s Hospital of The King’s Daughters, USA
15:00 – 15:20 Pharmacist practitioner: Innovating neurodegenerative disease pathways: Early cognitive decline screening through community pharmacy services
Mr Gonzalo Miguel Adsuar Meseguer, Cardenal Herrera University, Spain
15:20 – 15:55 Panel discussion with chairs, speakers and additional panellists
15 :55 – 16:00 Closing remarks by the chairs
Learning objectives: 1. Illustrate how innovation in neurodegenerative research translates to patient-centred pharmacy practice. 2. Identify pharmacists’ roles in supporting patients and families through complex care. 3. Highlight intergenerational and interdisciplinary collaboration as a driver of translational success. Take home messages: Connecting discovery and practice empowers pharmacists and scientists to deliver better care for patients and families living with neurodegenerative diseases. FIP Development Goals: FIP DG 2 FIP DG 7 FIP DG 15 To learn more about these FIP Development Goals, click on the links below. FIP Development Goal 2: Early Career Training Strategy FIP Development Goal 7: Advancing Integrated Services FIP Development Goal 15: People-Centred Care


Chairs & speakers

Mr Gonzalo M. Adsuar Meseguer
Cardenal Herrera University

Pharmacist practitioner: Innovating neurodegenerative disease pathways: Early cognitive decline screening through community pharmacy services

Ms Nikolina Biskic
Executive Committee associate member of the FIP Industrial Pharmacy Section

Chairing of 83 - Neurodegenerative diseases: From innovation to patient impact

Ms Christina Hellauer
Children’s Hospital of The King’s Daughters

Advanced treatments for neuromuscular disorders: Real world experiences in a global population

Prof. Michael Ward
Co-chair FIP Congress Programme Development Group

Chairing of 83 - Neurodegenerative diseases: From innovation to patient impact

loading